Back to Authors

Sullivan, Kaede V.

https://orcid.org/0000-0001-6654-5861

Mayo Clinic

Temple University

Citations 2

Considerations from the College of American Pathologists for Implementation of an Assay for SARS-CoV-2 Testing after a Change in Regulatory Status
Peaper, David R. , Rhoads, Daniel D. , Sullivan, Kaede V. , Couturier, Marc Roger , Humphries, Romney M. , Nolte, Frederick S. , Rowlinson, Marie‐Claire , She, Rosemary C. , Simner, Patricia J. , Theel, Elitza S. , Wojewoda, Christina , Nolte, Frederick S , Simner, Patricia J , Theel, Elitza S , Wojewoda, Christina M , Humphries, Romney , Rhoads, Daniel D , Martin, Isabella W.

Journal of Clinical Microbiology | July 14, 2021 | Volume: 59 | Issue: 10 | Pages: No page available

10.1128/jcm.01167-21 Get It

The U.S. Food & Drug Administration (FDA) regulates the marketing of manufacturers’ in vitro diagnostic tests (IVDs), including assays for the detection of SARS-CoV-2.